HK1061805A1 - 5-Ht 1a receptor subtype agonist - Google Patents

5-Ht 1a receptor subtype agonist

Info

Publication number
HK1061805A1
HK1061805A1 HK04104847A HK04104847A HK1061805A1 HK 1061805 A1 HK1061805 A1 HK 1061805A1 HK 04104847 A HK04104847 A HK 04104847A HK 04104847 A HK04104847 A HK 04104847A HK 1061805 A1 HK1061805 A1 HK 1061805A1
Authority
HK
Hong Kong
Prior art keywords
receptor subtype
subtype agonist
agonist
receptor
subtype
Prior art date
Application number
HK04104847A
Other languages
English (en)
Inventor
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1061805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1061805A1 publication Critical patent/HK1061805A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK04104847A 2001-01-29 2004-07-06 5-Ht 1a receptor subtype agonist HK1061805A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en) 2001-01-29 2002-01-29 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number Publication Date
HK1061805A1 true HK1061805A1 (en) 2004-10-08

Family

ID=25087808

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04104847A HK1061805A1 (en) 2001-01-29 2004-07-06 5-Ht 1a receptor subtype agonist
HK06111985.8A HK1091403A1 (en) 2001-01-29 2006-11-01 5-ht 1a receptor subtype agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06111985.8A HK1091403A1 (en) 2001-01-29 2006-11-01 5-ht 1a receptor subtype agonist

Country Status (20)

Country Link
EP (3) EP1712225B1 (ja)
JP (4) JP4178032B2 (ja)
KR (5) KR100601073B1 (ja)
CN (3) CN100450485C (ja)
AR (4) AR032641A1 (ja)
AT (3) ATE362763T1 (ja)
AU (4) AU2002226752C1 (ja)
BR (1) BR0206237A (ja)
CA (2) CA2700314C (ja)
CY (3) CY1105631T1 (ja)
DE (3) DE60239711D1 (ja)
DK (3) DK1355639T3 (ja)
ES (3) ES2286755T3 (ja)
HK (2) HK1061805A1 (ja)
MX (2) MXPA03006603A (ja)
MY (1) MY129355A (ja)
PH (1) PH12014500937A1 (ja)
PT (3) PT1712225E (ja)
TW (2) TWI302832B (ja)
WO (1) WO2002060423A2 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US7973043B2 (en) * 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
CN102172401A (zh) * 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) * 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1992020655A1 (en) * 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
AU730856C (en) * 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
ES2188970T3 (es) * 1996-08-27 2003-07-01 Wyeth Corp 4-aminoetoxiindoles, como agonistas d2 de dopamina y como ligandos de los receptores 5ht1a.
WO1999038864A1 (en) * 1998-02-03 1999-08-05 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
JP2002511450A (ja) * 1998-04-13 2002-04-16 アメリカン・ホーム・プロダクツ・コーポレイション ４−アミノ−（エチルアミノ）−オキソインドールドパミン自己受容体作動薬
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
PT1627639E (pt) * 2001-06-19 2010-03-01 Norbert Mueller Utilização de inibidores da cox-2 para o tratamento de distúrbios afectivos
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
ATE362763T1 (de) 2007-06-15
KR100653591B1 (ko) 2006-12-05
KR100763288B1 (ko) 2007-10-04
PH12014500937A1 (en) 2015-09-21
MY129355A (en) 2007-03-30
AU2005201772A1 (en) 2005-05-19
AR080849A2 (es) 2012-05-09
CN100450485C (zh) 2009-01-14
JP5683010B2 (ja) 2015-03-11
EP1355639A2 (en) 2003-10-29
CN1813745A (zh) 2006-08-09
PT1712225E (pt) 2011-04-18
KR20030065570A (ko) 2003-08-06
KR20050107822A (ko) 2005-11-15
CA2700314A1 (en) 2002-08-08
EP1621198A2 (en) 2006-02-01
AR099754A2 (es) 2016-08-17
TW200522960A (en) 2005-07-16
AU2005201772C1 (en) 2010-06-03
AU2002226752B2 (en) 2005-03-17
KR20060028485A (ko) 2006-03-29
CY1108031T1 (el) 2013-09-04
ES2363366T3 (es) 2011-08-02
KR100601073B1 (ko) 2006-07-19
AU2009233591A1 (en) 2009-11-19
AR032641A1 (es) 2003-11-19
DK1355639T3 (da) 2006-08-14
KR100713607B1 (ko) 2007-05-02
CA2429496A1 (en) 2002-08-08
BR0206237A (pt) 2003-12-23
DK1621198T3 (da) 2007-09-24
JP4896831B2 (ja) 2012-03-14
CA2700314C (en) 2012-04-24
JP2011225587A (ja) 2011-11-10
TWI302832B (en) 2008-11-11
WO2002060423A3 (en) 2003-04-10
AU2005201772B2 (en) 2007-05-17
ATE322894T1 (de) 2006-04-15
KR100825705B1 (ko) 2008-04-29
CN1239154C (zh) 2006-02-01
DK1712225T3 (da) 2011-06-20
AU2007201701A1 (en) 2007-05-10
JP2011184460A (ja) 2011-09-22
CA2429496C (en) 2010-10-19
AU2007201701B2 (en) 2010-06-17
EP1621198A3 (en) 2006-04-12
MX344556B (es) 2016-12-20
EP1712225B1 (en) 2011-04-06
AU2002226752C1 (en) 2010-02-18
DE60210581D1 (en) 2006-05-24
HK1091403A1 (en) 2007-01-19
JP2004517937A (ja) 2004-06-17
DE60239711D1 (de) 2011-05-19
ATE504293T1 (de) 2011-04-15
PT1621198E (pt) 2007-06-08
EP1355639B1 (en) 2006-04-12
DE60210581T2 (de) 2007-04-05
EP1621198B1 (en) 2007-05-23
CN1879624A (zh) 2006-12-20
JP2007297405A (ja) 2007-11-15
CY1105631T1 (el) 2010-12-22
ES2261652T3 (es) 2006-11-16
CY1111392T1 (el) 2015-08-05
MXPA03006603A (es) 2004-02-12
PT1355639E (pt) 2006-06-30
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
KR20070065425A (ko) 2007-06-22
WO2002060423A2 (en) 2002-08-08
EP1712225A1 (en) 2006-10-18
JP4178032B2 (ja) 2008-11-12
DE60220325T2 (de) 2008-01-17
DE60220325D1 (de) 2007-07-05
KR20060085260A (ko) 2006-07-26
ES2286755T3 (es) 2007-12-01
TWI331919B (en) 2010-10-21
CN1484524A (zh) 2004-03-24

Similar Documents

Publication Publication Date Title
HK1091403A1 (en) 5-ht 1a receptor subtype agonist
AU2002367424A1 (en) Androgen receptor antagonists
IL158807A0 (en) 5-ht receptor ligands and uses thereof
HK1076459A1 (en) 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AUPR833401A0 (en) G protein-coupled receptor antagonists
EP1351933A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
HRP20030031A2 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
GB0203412D0 (en) 5-HT 2B receptor antagonists
EP1520856A4 (en) ANDROGEN RECEPTOR AGONIST
AU2001253172A1 (en) Il-8 receptor antagonists
AU2001241896A1 (en) Il-8 receptor antagonists
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
IL144810A0 (en) Dopamine d1 receptor agonist compounds
AU2001245605A1 (en) Il-8 receptor antagonists
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
IL158063A0 (en) Crf receptor antagonists
GB0203413D0 (en) 5-HT 2B receptor antagonists
AU2002338040A1 (en) Receptor antagonist
GB0125183D0 (en) Receptor
GB0110662D0 (en) Receptor

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220128